stockmarketproxy
/
PFENYSE SEC EDGAR

PFIZER INC

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 78003
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$62.6B$63.6B$58.5B$100.3B$81.3B
Gross Profit——————
Operating Income——————
Net Income$7.8B$8.0B$2.1B$31.4B$22.0B
Operating CF$11.7B$12.7B$8.7B$29.3B$32.6B
Capex$2.6B$2.9B$3.9B$3.2B$2.7B
Free Cash Flow$9.1B$9.8B$4.8B$26.0B$29.9B
Buybacks—$0$0$2.0B$0
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin12.4%12.6%3.6%31.3%27.0%
FCF Margin14.5%15.5%8.2%25.9%36.7%
R&D / Revenue——————
Effective Tax-3.5%-0.3%-105.4%9.6%7.6%
Debt / Equity0.710.650.690.340.47
Buybacks / FCF—0.0%0.0%7.7%0.0%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
PFE
277:1
ROIV
518:1
AXSM
23:1
COGT
95:1
ABT
166:1
PTCT
7:1
CEO total comp
PFE
$28M
ROIV
$163M
AXSM
$34M
COGT
$28M
ABT
$24M
PTCT
$23M
Net Margin
PFE
12.4%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
ABT
14.7%
PTCT
39.4%